Do older patients with myeloma respond as well to ide-cel as younger patients?
Older and frail adult patients with multiple myeloma treated with idecabtagene vicleucel (ide-cel), a B-cell maturation agent targeting chimeric antigen receptor (CAR)-T product, have comparable treatment outcomes to younger patients, according to a retrospective analysis. The research was published online in Blood Advances and led by Othman Salim Akhtar, MD, of the Medical College of Wisconsin and the Center for International Blood and Marrow Transplantation Research in Milwaukee, Wisconsin. The retrospective study used data from the Center for International Blood and Marrow Transplantation (CIBMTR) on US patients who received ide-cel between May 2021 to June 2023 with at least 100 days of follow-up. No differences were found in overall response (OR) or complete response (CR) at six months by age group. Progression-free survival (PFS) at six months was higher in patients ≥70 years of age (68.3% vs 60.4%, P=0.02). Overall survival (OS) at six months was comparable between the age…
